Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab

14-Jan-2011 - Germany

Sandoz announced that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera®), a monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis.

The phase II study in patients suffering from rheumatoid arthritis aims to demonstrate bioequivalence to the reference product, and will collect data on pharmacokinetics and pharmacodynamics as well as efficacy and safety data.

Over the past few years Sandoz has developed a robust, high-yield and large-scale process for the production of biosimilar rituximab in its own facilities in Schaftenau, Austria. To ensure biosimilarity with the reference product, a comprehensive physico-chemical and functional analysis of the product was conducted using modern bioanalytic techniques, followed by further studies. The data suggest that Sandoz's biosimilar rituximab is highly similar to the reference product, justifying initiation of clinical studies in patients.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Last viewed contents

Chemokine Therapeutics Announces Patent Issuance for Chemokine Analogs for the Treatment of Human Disease

AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

Astex ranked top biotech company for the second year running in The Sunday Times Microsoft Tech Track 100

Researchers produce nanodiamonds capable of delivering medicinal and cosmetic remedies through the skin - Using advanced optics technology, the exact location and concentration of nanodiamonds can be monitored non-invasively, eliminating the need for a biopsy

Researchers produce nanodiamonds capable of delivering medicinal and cosmetic remedies through the skin - Using advanced optics technology, the exact location and concentration of nanodiamonds can be monitored non-invasively, eliminating the need for a biopsy

Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

Cell Medica begins commercial production at newly licensed cell therapy manufacturing facility in Germany

Biotage AB Acquires Separtis Holding AG for 1.4M Euros (13M SEK) and Completes EU Distribution Consolidation

A*STAR Scientists Discover Key Component in the Mother's Egg Critical for Survival of Newly Formed Embryo

Development of wireless multi-parameter monitoring system for viruses and very slow growing microorganisms - Biophage Pharma signs collaborates with National Taiwan University

New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications

ES Cell International and ITI Life Sciences sign Licence Agreement for use of novel Stem Cell Technologies

To-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases